A Prospective, Multicenter Trial to Evaluate Efficacy and Safety of Cenegermin-bkbj (20 mcg/mL) Ophthalmic Solution on Corneal Thickness Via Anterior Segment Optical Coherence Tomography (AS-OCT) in Stage 3 Neurotrophic Keratitis
Latest Information Update: 04 Dec 2024
At a glance
- Drugs Cenegermin (Primary)
- Indications Keratitis; Neurotrophic keratopathy
- Focus Therapeutic Use
- Acronyms IMAGO
- Sponsors Dompe Farmaceutici
Most Recent Events
- 16 May 2024 New trial record